摘要
目的:观察埃索美拉唑肠溶胶囊治疗幽门螺杆菌(Hp)的疗效,并评价其安全性。方法:59例Hp阳性的十二指肠溃疡患者随机分为试验组(29例)与对照组(27例),分别服用埃索美拉唑肠溶胶囊或埃索美拉唑镁肠溶片40mg(qd)及克拉霉素500mg(bid)、替硝唑500mg(bid),连用7d。结果:试验组Hp根除率为62.07%,对照组为37.04%,2组间无显著性差异(P>0.05);2组不良反应发生率相似,试验组为17.24%,对照组为14.81%。结论:埃索美拉唑肠溶胶囊治疗Hp效果与埃索美拉唑镁肠溶片相似,安全性好。
OBJECTIVE： To observe the curative efficacy of esomeprazole enteric - coated capsule in the eradication of helicobacter pylori and to evaluate its safety.METHODS： A total of 59 Hp positive patients with active duodenal ulcer were randomly divided into two groups ： the trial group（n = 29） were assigned to receive esomeprazole enteric - coated capsules 40mg qd in combination with tinidazole 500mg bid and clarithromycin 500mg bid for 7 consecutive days, and the control group（n = 27） to receive esomeprazole magnesium 40mg qd in combination with tinidazole 500mg bid and clarithromycin 500mg bid for 7 consecutive days.RESULTS：Eradication rates were 62.07% with domestic esomeprazole enteric- coated capsules and 37.04% with esomeprazole magnesium, showing no significant differences between the two groups（P 〉 0.05） .The incidences of ADR in the two groups（17.24% vs. 14.81% ） were near to each other.CONCLUSION： The esomeprazole enteric- coated capsules and esomeprazole magnesium - based triple therapy regimens are therapeutically equivalent in the eradication of Hp and it has a good safety.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第26期2044-2046,共3页
China Pharmacy
关键词
埃索美拉唑
幽门螺杆菌
疗效
Esomeprazole
Helicobacter pylori
Therapeutic efficacy
